Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic Era.

ABSTRACT: The treatment landscape for newly diagnosed classical Hodgkin lymphoma (cHL) has seen remarkable advancements over the past decade, which have been fueled by improved prognostication and response-adapted techniques, and primarily driven by randomized clinical trials, especially via the incorporation of novel targeted therapeutic agents into frontline therapy. The studies include several recent landmark clinical trials that integrated novel targeted therapeutic agents into frontline therapy for adolescents and adults with cHL. For early-stage disease, the completion of PET-based response-adapted studies has resulted in refined therapeutic approaches, particularly informing the amount and type of chemotherapy as well as the impact of radiotherapy, balancing immediate efficacy with the mitiga

SUBMITTER: Evens AM 

PROVIDER: S-EPMC12167649 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature